Clinical study of enzalutamide on castration resistant prostate cancer
Not Applicable
Completed
- Conditions
- Castration resistant prostate cancer
- Registration Number
- JPRN-UMIN000014702
- Lead Sponsor
- CRPC-TRG: castration resistant prostate cancer treatment research group
- Brief Summary
Total 104 patients were enrolled with age of 53 to 88 years. PSA responses over 50% and 90% were 62.5% and 25.0%. Response duration of 50% response was 7.0 month. Median overall survival was 133.3 weeks with median. Prognostic factor affecing to overall survival was docetaxel treatment history, hemoglobin levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 104
Inclusion Criteria
Not provided
Exclusion Criteria
1 Epileptic state patients 2 Brain damage, apoplexy, brain metastatis, active epidural metastatis of cranium 3 Hypersensitivity to enzalutamide or its component 4 Severe liver dysfunction 5 Impropriate state judged by charged doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method